非血管新生型AMDに続発する非中心窩地理的萎縮症におけるGAL-101、2%点眼液の第2相有効性と安全性研究 (eDREAM)
非新生血管年齢に続発する非中心窩地理性萎縮患者におけるGAL-101 2%点眼液の有効性と安全性を調査するための第2相、二重マスク、無作為化、多施設共同、並行群間プラセボ対照試験-関連する黄斑変性症:EDREAM 研究
Age-related macular degeneration (AMD) affects millions of elderly patients. When advanced, there is Geographic Atrophy (GA) in the retina. This means that there is an area with a loss of light-sensitive cells, called photoreceptors. That part of the retina can no longer see. Atrophy begins as a small spot in the retina distant from the fovea which is the part of the retina responsible for sharp central vision. The GA grows, and when it reaches the fovea, vision is severely diminished, and details cannot be seen anymore. The purpose of the eDREAM study is to understand if GAL-101 can slow the growth of GA and prevent it from reaching the fovea. GAL-101 is given as eyedrops. eDREAM patients will administer study eyedrops every day. Patients will be assigned by chance (randomly) to receive either eye-drops that contain the new medication, GAL-101, or eyedrops without the active drug (Placebo). Neither patients nor doctors will know which treatment was assigned to each patient until the end of the study.
調査の概要
詳細な説明
In this study, if both eyes qualify for the study, the eye with the better BCVA will be defined as the study eye. If both eyes qualify for the study and have identical BCVA, then the eye with higher baseline peripheral retinal degenerations (PRD) will be defined as the study eye. If baseline PRD is identical, then the right eye (OD) will be defined as the study eye. Only the study eye will be dosed with the Investigation Medicinal Product (IMP).
During visits, patients will administer 3 applications of 1 drop of GAL-101 or a matching Placebo that does not contain the active pharmaceutical ingredient (API) at 5-minute intervals (i.e., 1st application, wait 5 minutes, 2nd application, wait 5 minutes, 3rd application), under the supervision of trained and authorized study personnel. In between visits, patients will be instructed to administer 2 applications of 1 drop at 5-minute intervals once a day.
The study will be comprised of a 12- to 24-month treatment period determined individually according to patients' overall placement in global study randomization. All patients will participate at least 12 months of treatment. The visit schedule includes the following: Screening visits (Visit 1a and 1b) for image capture and confirmation of study eligibility by a reading center; Baseline/Randomization/Day 1 (Visit 2); a phone call at 2 weeks; and on-treatment clinic visits for safety and efficacy evaluations at 1 month, 3 months, 6 months, 9 months, and 12 months. Patients will continue to attend on-treatment clinic visits at 3-month intervals after 12 months until the last patient randomized in the study has completed 12 months of study treatment.
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Galimedix Inc. c/o Imperial CRS, MD
- 電話番号:+1 (301) 9179191
- メール:info@galimedix.com
研究連絡先のバックアップ
- 名前:Luciana Summo, PhD
- メール:info@galimedix.com
研究場所
-
-
-
Kildare、アイルランド、W91 W535
- 募集
- UPMC Kildare Hospital Prosperous Rd Clane, Kildare Ireland
-
主任研究者:
- Eugene Ng, MD
-
コンタクト:
- Hiella Akhundova
- 電話番号:+353 89 411 2119
- メール:hiella.a@ioes.ie
-
Waterford、アイルランド、X91 DH9W
- 募集
- Institute of Eye Surgery (IOES Waterford)
-
主任研究者:
- Eugene Ng, MD
-
コンタクト:
- Emmanuel Ankamah
- 電話番号:+353 89 411 2119
- メール:emmanuel.a@ioes.ie
-
-
-
-
California
-
Beverly Hills、California、アメリカ、90211
- 募集
- Retina-Vitreous Associates Medical Group
-
主任研究者:
- David Boyer, MD
-
コンタクト:
- Rahul Araza
- 電話番号:3 (310) 289-2478
- メール:raraza@laretina.com
-
Walnut Creek、California、アメリカ、94598
- 募集
- Bay Area Retina Associates
-
主任研究者:
- Roger Goldberg, MD
-
コンタクト:
- Karrie Padilla
- 電話番号:925-265-4146
- メール:kpadilla@bayarearetina.com
-
-
Maryland
-
Hagerstown、Maryland、アメリカ、21740
- 一時停止
- Cumberland Valley Retina Consultants
-
-
-
-
-
Yerevan、アルメニア、0048
- 募集
- Ophthalmological Center After S.V. Malayan
-
コンタクト:
- Ani Babayan
- 電話番号:+37494909990
- メール:babayanani88@yahoo.com
-
主任研究者:
- Lilit Voskanyan, MD, PhD
-
-
-
-
-
Jerusalem、イスラエル、9112001
- 募集
- Hadassah Medical Center
-
コンタクト:
- Michal Shpigel
- 電話番号:972-54-4575921
- メール:smichal@hadassah.org.il
-
主任研究者:
- Tareq Jaouni, MD
-
Tel Aviv、イスラエル、6423906
- 募集
- Tel Aviv Medical Center
-
コンタクト:
- Marina Gordon
- 電話番号:972-3-6947371
- メール:marinago@tlvmc.gov.il
-
主任研究者:
- Omer Trivizki, MD
-
-
-
-
Milano
-
Milan、Milano、イタリア、20123
- 募集
- Medical Retina & Imaging Unit, IRCCS MultiMedica, Ospedale San Giuseppe
-
コンタクト:
- Mara Cattaneo Study Coordinator
- メール:mara.cattaneo@multimedica.it
-
主任研究者:
- Stela Vujosevic, MD
-
Milan、Milano、イタリア、20132
- 募集
- Unità di Oculistica, IRCCS Ospedale San Raffaele
-
コンタクト:
- Adelaide Pina Study Coordinator
- 電話番号:0226433545
- メール:pina.adelaide@hsr.it
-
主任研究者:
- Francesco Bandello, MD
-
-
Roma
-
Roma、Roma、イタリア、00184
- 募集
- UOS Retina Medica, P.O. Britannico, IRCCS Fondazione G.B. Bietti per lo Studio e la Ricerca in Oftalmologia
-
コンタクト:
- Ilaria Casale, Dr
- メール:ilaria.casale@fondazionebietti.it
-
主任研究者:
- Mariacristina Parravanno, MD
-
-
-
-
-
Tbilisi、グルジア、0162
- 募集
- Akhali Mzera Limited
-
コンタクト:
- Revaz Bezarashvili
- 電話番号:(+995) 555 55 54 82
- メール:rezieye@gmail.com
-
主任研究者:
- Shalva Skhirtladze, MD
-
Tbilisi、グルジア、0186
- 募集
- Caucasus Medical Centre LLC
-
コンタクト:
- Sopio Tsiklauri, MD
- 電話番号:(+995) 595 974 774
- メール:soffia01@yahoo.com
-
主任研究者:
- Mikheil Omiadze, MD, PhD
-
-
-
-
-
Bonn、ドイツ、53127
- 募集
- Universitäts-Augenklinik Bonn
-
主任研究者:
- Kristina Pfau, MD
-
コンタクト:
- Joanna Czauderna Study Coordinator
- 電話番号:0228 287-11493
- メール:Joanna.Czauderna@ukbonn.de
-
Freiburg im Breisgau、ドイツ、79106
- 募集
- Universitätsklinikum Freiburg Klinik für Augenheilkunde
-
主任研究者:
- Hansjuergen Agostini, MD
-
コンタクト:
- Christine Kremer
- 電話番号:+49 761 270 40231
- メール:christine.kremer@uniklinik-freiburg.de
-
Hanover、ドイツ、30625
- 募集
- Medizinische Hochschule Hannover Augenklinik
-
コンタクト:
- Irene Oluwatoba-Popoola
- メール:Oluwatoba-popoola.irene@mh-hannover.de
-
主任研究者:
- Ekaterina Sokolenko, MD
-
Neubrandenburg、ドイツ、17036
- 募集
- Dietrich Bonhoeffer Klinikum
-
コンタクト:
- Ulrike Holland
- 電話番号:+49 395 775 13427
- メール:aug-st2@dbknb.de
-
主任研究者:
- Christian Brinkmann, MD
-
Tübingen、ドイツ、72076
- 募集
- Universitätsklinikum Tübingen, Department für Augenheilkunde.
-
コンタクト:
- Angela Geiger
- メール:Felix.Reichel@med.uni-tuebingen.de
-
主任研究者:
- Felix Reichel, MD
-
Ulm、ドイツ、89075
- まだ募集していません
- UNIVERSITÄTSKLINIKUM ULM Klinik für Augenheilkunde
-
コンタクト:
- Julia Ciboci
- メール:Julia.Ciboci@uniklinik-ulm.de
-
主任研究者:
- Armin Wolf, MD
-
-
-
-
-
Bordeaux、フランス、33000
- 募集
- Centre Rétine Gallien
-
コンタクト:
- Manon Demeurs
- 電話番号:33 (5) 56 11 32 25
- メール:arc@retinegallien.com
-
主任研究者:
- Eric Fourmaux, MD
-
Lyon、フランス、69317
- 募集
- Hopital de La Croix-Rousse Service D'Ophtalmologie Groupement Hospitalier Nord Hospices Civils de Lyon
-
コンタクト:
- Roxane Bai
- 電話番号:+33 (0)4 26 73 27 02
- メール:roxane.bai@chu-lyon.fr
-
主任研究者:
- Laurent KODJIKIAN, MD
-
Marseille、フランス、13008
- 募集
- Centre Monticelli Paradis d'Ophtalmologie
-
コンタクト:
- Agné Devin Dr.
- 電話番号:049116 05 84
- メール:agne.retine@gmail.com
-
主任研究者:
- François Devin, MD
-
Paris、フランス、75006
- 募集
- Centre Ophtalmologique Odéon
-
コンタクト:
- Sumeyye OZALTUN
- メール:ozalt.sumeyye@gmail.com
-
コンタクト:
- Favard, MD
-
主任研究者:
- Catherine Favard, MD
-
Tours、フランス、37540
- 募集
- Centre médico-chirurgical de Touraine
-
コンタクト:
- Sarah Van Herreweghe
- 電話番号:33 (0)2 47 64 67 27
- メール:svanherreweghe6@gmail.com
-
主任研究者:
- Sam Razavi, MD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
≥55 years of age
-
Willing and able to provide written informed consent
-
Willing and able to comply with the study schedule and study assessments
-
Able to successfully administer ophthalmic solution or have an appropriate designee (e.g., family member, health care professional) who can administer ophthalmic solution
-
BCVA of ≥50 letters in the study eye using Early Treatment Diabetic Retinopathy Study (ETDRS) chart (i.e., 20/100 Snellen equivalent). Criterion will be confirmed at Baseline
-
Refractive error between +3 and -6 diopters spherical equivalent in the study eye
-
Sufficiently clear ocular media and adequate pupillary dilation to permit quality fundus imaging of the study eye, in the opinion of the Investigator. Criterion will be confirmed at Baseline
-
Diagnosed with non-foveal GA secondary to non-neovascular AMD in the study eye, as confirmed by the reading center
- Well-delineated cumulative GA area between 1.25 and 12.0 mm2
- If GA is multifocal, at least 1 lesion ≥1.25 mm2
- GA lesions must be located outside a ≥100 µm radius from the center point of the fovea (i.e., this area must have intact retinal pigment epithelium [RPE] and outer retina)
- GA lesions must be located (partially or wholly) within a 2000 µm radius from the center point of the fovea
- GA lesions must be completely located within FAF imaging field (field 2 to 30-degree image centered on the fovea). GA lesion borders must be >300 µm from image edges
- GA lesions must be >300 µm from the optic disc and/or peripapillary atrophy
- Area of PRD must be cumulatively between 7.25 and 25.0 mm2
Exclusion Criteria:
-
Presence or history of choroidal neovascularization (CNV). Criterion will be confirmed at Baseline
-
History of laser therapy in the macular region, regardless of indication
-
History of herpes zoster
-
Ophthalmic disease or condition that requires or is likely to require surgery during the study period
-
GA with cumulative area <1.25 mm2
-
Any GA lesion within 100 µm radius from the center point of the fovea
-
Axial length >26 mm
-
Any ocular disease or condition other than non-neovascular AMD that may, in the opinion of the Investigator, interfere with study assessments, patient adherence to the study schedule, or interpretation of study data (e.g., epiretinal membrane, macular hole, glaucomatous optic neuropathy, etc.)
-
Intraocular surgery (including cataract extraction and crystalline lens replacement) within 3 months before Visit 1a or yttrium aluminum garnet (YAG) surgery within 2 months before Visit 1a, or planned either during the study period
-
Use of pegcetacoplan or avacincaptad pegol within 6 months before Visit 1a, or planned use during the study period
-
Use of any prescription or over-the-counter ophthalmic medication within 1 month before Visit 1a or planned use during the study period
-
Use of rigid contact lenses within 1 month before Visit 1a or planned use during the study period
Non-study Eye:
-
BCVA of <5 letters using ETDRS chart (i.e., 20/800 Snellen equivalent)
Either Eye:
-
History of uveitis
-
GA secondary to any condition other than non-neovascular AMD
-
History of active ocular infection or inflammation within 3 months before Visit 1a or Baseline. Criterion will be confirmed at Baseline
-
Underwent investigational treatment for AMD within 6 months before Visit 1a
General Exclusion Criteria:
-
History of therapeutic radiation to the cranium
-
Known allergy or hypersensitivity to the investigational medicinal product (IMP) or any of its excipients
-
History of malignant disease
-
Use of hydroxychloroquine within 1 month before Visit 1a, or planned use during the study period
-
Participated or plan to participate in any other IMP study within 1 month before Visit 1a or during the study period
-
Use of lutein >10 mg per day or zeaxanthin >2 mg per day within 1 month before Visit 1a, or planned use during the study period
-
Any medical condition (including mental), in the opinion of the Investigator, that could interfere with study assessments, patient adherence to the study schedule, or interpretation of study data
-
Screening laboratory values, in the opinion of the Investigator, that make the patient unsuitable for study participation
-
Pregnant, nursing, or planning a pregnancy during the study. Criterion will be confirmed at Baseline
-
Unwilling or unable to use an acceptable method of contraception throughout the study if a woman of childbearing potential (WOCBP) or if a sexual partner of a WOCBP
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:GAL-101 ophthalmic solution
Patient will apply daily 2 eye drops of GAL-101 at 5 minutes interval |
Patient will apply daily 2 eye drops of GAL-101 at 5 minutes interval |
|
プラセボコンパレーター:Placebo
Patient will apply daily 2 eye drops ofPlacebo at 5 minutes interval |
Patient will apply daily 2 eye drops of Placebo at 5 minutes interval |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Efficacy of GAL-101 ophthalmic solution in reducing the rate of change in GA lesion size.
時間枠:From baseline to last on-treatment visit (48 up to 96 weeks)
|
Comparison between groups of annual rate of change in the area of GA as measured by fundus autofluorescence (FAF). |
From baseline to last on-treatment visit (48 up to 96 weeks)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Efficacy of GAL-101 ophthalmic solution in reducing the rate of change in photoreceptor degeneration (PRD) in eyes with GA
時間枠:From baseline to last on-treatment visit (48 up to 96 weeks)
|
Comparison between groups of annual rate of change in the area of PRD as measured by optical coherence tomography (OCT) |
From baseline to last on-treatment visit (48 up to 96 weeks)
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- GAL-101-C0201
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。